Cell and organ bioengineering technology as applied to gastrointestinal diseases

Giuseppe Orlando, Juan Domínguez Bendala, Thomas Shupe, Christopher Bergman, Khalil N. Bitar, Christopher Booth, Marco Carbone, Kenneth L. Koch, Jan P. Lerut, James M. Neuberger, Bryon Petersen, Camillo Ricordi, Anthony Atala, Robert J. Stratta, Shay Soker

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

This review illustrates promising regenerative medicine technologies that are being developed for the treatment of gastrointestinal diseases. The main strategies under validation to bioengineer or regenerate liver, pancreas, or parts of the digestive tract are twofold: engineering of progenitor cells and seeding of cells on supporting scaffold material. In the first case, stem cells are initially expanded under standard tissue culture conditions. Thereafter, these cells may either be delivered directly to the tissue or organ of interest, or they may be loaded onto a synthetic or natural three-dimensional scaffold that is capable of enhancing cell viability and function. The new construct harbouring the cells usually undergoes a maturation phase within a bioreactor. Within the bioreactor, cells are conditioned to adopt a phenotype similar to that displayed in the native organ. The specific nature of the scaffold within the bioreactor is critical for the development of this high-function phenotype. Efforts to bioengineer or regenerate gastrointestinal tract, liver and pancreas have yielded promising results and have demonstrated the immense potential of regenerative medicine. However, a myriad of technical hurdles must be overcome before transplantable, engineered organs become a reality.

Original languageEnglish
Pages (from-to)774-786
Number of pages13
JournalGut
Volume62
Issue number5
DOIs
Publication statusPublished - May 2013

Fingerprint

Bioengineering
Gastrointestinal Diseases
Bioreactors
Technology
Regenerative Medicine
Gastrointestinal Tract
Pancreas
Stem Cells
Phenotype
Liver
Cell Survival

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Orlando, G., Bendala, J. D., Shupe, T., Bergman, C., Bitar, K. N., Booth, C., ... Soker, S. (2013). Cell and organ bioengineering technology as applied to gastrointestinal diseases. Gut, 62(5), 774-786. https://doi.org/10.1136/gutjnl-2011-301111

Cell and organ bioengineering technology as applied to gastrointestinal diseases. / Orlando, Giuseppe; Bendala, Juan Domínguez; Shupe, Thomas; Bergman, Christopher; Bitar, Khalil N.; Booth, Christopher; Carbone, Marco; Koch, Kenneth L.; Lerut, Jan P.; Neuberger, James M.; Petersen, Bryon; Ricordi, Camillo; Atala, Anthony; Stratta, Robert J.; Soker, Shay.

In: Gut, Vol. 62, No. 5, 05.2013, p. 774-786.

Research output: Contribution to journalArticle

Orlando, G, Bendala, JD, Shupe, T, Bergman, C, Bitar, KN, Booth, C, Carbone, M, Koch, KL, Lerut, JP, Neuberger, JM, Petersen, B, Ricordi, C, Atala, A, Stratta, RJ & Soker, S 2013, 'Cell and organ bioengineering technology as applied to gastrointestinal diseases', Gut, vol. 62, no. 5, pp. 774-786. https://doi.org/10.1136/gutjnl-2011-301111
Orlando G, Bendala JD, Shupe T, Bergman C, Bitar KN, Booth C et al. Cell and organ bioengineering technology as applied to gastrointestinal diseases. Gut. 2013 May;62(5):774-786. https://doi.org/10.1136/gutjnl-2011-301111
Orlando, Giuseppe ; Bendala, Juan Domínguez ; Shupe, Thomas ; Bergman, Christopher ; Bitar, Khalil N. ; Booth, Christopher ; Carbone, Marco ; Koch, Kenneth L. ; Lerut, Jan P. ; Neuberger, James M. ; Petersen, Bryon ; Ricordi, Camillo ; Atala, Anthony ; Stratta, Robert J. ; Soker, Shay. / Cell and organ bioengineering technology as applied to gastrointestinal diseases. In: Gut. 2013 ; Vol. 62, No. 5. pp. 774-786.
@article{9930f12a54bf4337a2228e1a0fffb875,
title = "Cell and organ bioengineering technology as applied to gastrointestinal diseases",
abstract = "This review illustrates promising regenerative medicine technologies that are being developed for the treatment of gastrointestinal diseases. The main strategies under validation to bioengineer or regenerate liver, pancreas, or parts of the digestive tract are twofold: engineering of progenitor cells and seeding of cells on supporting scaffold material. In the first case, stem cells are initially expanded under standard tissue culture conditions. Thereafter, these cells may either be delivered directly to the tissue or organ of interest, or they may be loaded onto a synthetic or natural three-dimensional scaffold that is capable of enhancing cell viability and function. The new construct harbouring the cells usually undergoes a maturation phase within a bioreactor. Within the bioreactor, cells are conditioned to adopt a phenotype similar to that displayed in the native organ. The specific nature of the scaffold within the bioreactor is critical for the development of this high-function phenotype. Efforts to bioengineer or regenerate gastrointestinal tract, liver and pancreas have yielded promising results and have demonstrated the immense potential of regenerative medicine. However, a myriad of technical hurdles must be overcome before transplantable, engineered organs become a reality.",
author = "Giuseppe Orlando and Bendala, {Juan Dom{\'i}nguez} and Thomas Shupe and Christopher Bergman and Bitar, {Khalil N.} and Christopher Booth and Marco Carbone and Koch, {Kenneth L.} and Lerut, {Jan P.} and Neuberger, {James M.} and Bryon Petersen and Camillo Ricordi and Anthony Atala and Stratta, {Robert J.} and Shay Soker",
year = "2013",
month = "5",
doi = "10.1136/gutjnl-2011-301111",
language = "English",
volume = "62",
pages = "774--786",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Cell and organ bioengineering technology as applied to gastrointestinal diseases

AU - Orlando, Giuseppe

AU - Bendala, Juan Domínguez

AU - Shupe, Thomas

AU - Bergman, Christopher

AU - Bitar, Khalil N.

AU - Booth, Christopher

AU - Carbone, Marco

AU - Koch, Kenneth L.

AU - Lerut, Jan P.

AU - Neuberger, James M.

AU - Petersen, Bryon

AU - Ricordi, Camillo

AU - Atala, Anthony

AU - Stratta, Robert J.

AU - Soker, Shay

PY - 2013/5

Y1 - 2013/5

N2 - This review illustrates promising regenerative medicine technologies that are being developed for the treatment of gastrointestinal diseases. The main strategies under validation to bioengineer or regenerate liver, pancreas, or parts of the digestive tract are twofold: engineering of progenitor cells and seeding of cells on supporting scaffold material. In the first case, stem cells are initially expanded under standard tissue culture conditions. Thereafter, these cells may either be delivered directly to the tissue or organ of interest, or they may be loaded onto a synthetic or natural three-dimensional scaffold that is capable of enhancing cell viability and function. The new construct harbouring the cells usually undergoes a maturation phase within a bioreactor. Within the bioreactor, cells are conditioned to adopt a phenotype similar to that displayed in the native organ. The specific nature of the scaffold within the bioreactor is critical for the development of this high-function phenotype. Efforts to bioengineer or regenerate gastrointestinal tract, liver and pancreas have yielded promising results and have demonstrated the immense potential of regenerative medicine. However, a myriad of technical hurdles must be overcome before transplantable, engineered organs become a reality.

AB - This review illustrates promising regenerative medicine technologies that are being developed for the treatment of gastrointestinal diseases. The main strategies under validation to bioengineer or regenerate liver, pancreas, or parts of the digestive tract are twofold: engineering of progenitor cells and seeding of cells on supporting scaffold material. In the first case, stem cells are initially expanded under standard tissue culture conditions. Thereafter, these cells may either be delivered directly to the tissue or organ of interest, or they may be loaded onto a synthetic or natural three-dimensional scaffold that is capable of enhancing cell viability and function. The new construct harbouring the cells usually undergoes a maturation phase within a bioreactor. Within the bioreactor, cells are conditioned to adopt a phenotype similar to that displayed in the native organ. The specific nature of the scaffold within the bioreactor is critical for the development of this high-function phenotype. Efforts to bioengineer or regenerate gastrointestinal tract, liver and pancreas have yielded promising results and have demonstrated the immense potential of regenerative medicine. However, a myriad of technical hurdles must be overcome before transplantable, engineered organs become a reality.

UR - http://www.scopus.com/inward/record.url?scp=84875818160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875818160&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2011-301111

DO - 10.1136/gutjnl-2011-301111

M3 - Article

VL - 62

SP - 774

EP - 786

JO - Gut

JF - Gut

SN - 0017-5749

IS - 5

ER -